Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-14-051875
Filing Date
2014-08-12
Accepted
2014-08-12 16:36:46
Documents
2
Period of Report
2014-08-11

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 2202
2 POA DOCUMENT poa.txt EX-24.3_534317 4068
  Complete submission text file 0001209191-14-051875.txt   7701
Mailing Address 1522 217TH PLACE S.E. BOTHELL WA 98021
Business Address 1522 217TH PLACE S.E. BOTHELL WA 98021 4254879500
ONCOGENEX PHARMACEUTICALS, INC. (Issuer) CIK: 0000949858 (see all company filings)

EIN.: 954343413 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2835 In Vitro & In Vivo Diagnostic Substances

Mailing Address 2401 FOURTH AVENUE, SUITE 1050 SEATTLE WA 98121
Business Address
Bencich John (Reporting) CIK: 0001477056 (see all company filings)

Type: 3 | Act: 34 | File No.: 033-80623 | Film No.: 141034408